Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled Phase I/II Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X, an Oral ICAM-1 and E-Selectin Inhibitor

NCT00457171 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00457171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00457171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled Phase I/II Study in Patients With Mild to Moderate Ulcerative Colitis Treated With GI-270384X, an Oral ICAM-1 and E-Selectin Inhibitor
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2004
Completion date
Not reported
Enrollment
16
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis